Skip to Content
Merck
All Photos(1)

Key Documents

SML0234

Sigma-Aldrich

Mitiglinide calcium

≥98% (HPLC)

Synonym(s):

(aS,3aR,7aS)-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calcium salt, KAD 1229, Mitiglinide hemicalcium salt, S 21403, [2(S)-cis]-Octahydro-g-oxo-a-(phenylmethyl)-2H-isoindole-2-butanoic acid calclium salt

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C19H24NO3·0.5Ca
CAS Number:
Molecular Weight:
334.44
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77

Quality Level

Assay

≥98% (HPLC)

form

powder

optical activity

[α]/D +5 to +9° (c=1, MeOH)

storage condition

desiccated

color

white to beige

solubility

DMSO: ≥10 mg/mL at warmed to 60 °C

storage temp.

room temp

SMILES string

O=C(C[C@H](Cc1ccccc1)C(=O)O[Ca]OC(=O)[C@H](CC(=O)N2C[C@H]3CCCC[C@H]3C2)Cc4ccccc4)N5C[C@H]6CCCC[C@H]6C5

InChI

1S/2C19H25NO3.Ca/c2*21-18(20-12-15-8-4-5-9-16(15)13-20)11-17(19(22)23)10-14-6-2-1-3-7-14;/h2*1-3,6-7,15-17H,4-5,8-13H2,(H,22,23);/q;;+2/p-2/t2*15-,16+,17-;/m00./s1

InChI key

PMRVFZXOCRHXFE-FMEJWYFOSA-L

Biochem/physiol Actions

Mitiglinide is a drug for the treatment of type 2 diabetes. It is a highly selective KATP channel antagonist Mitiglinide is a hypoglycemic agent that closes adenosine triphosphate (ATP)–sensitive potassium channels (KATP channel s) in the pancreatic β-islet cells.

Features and Benefits

This compound is featured on the Potassium Channels page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

X Gao
The Journal of international medical research, 37(3), 812-821 (2009-07-11)
This study investigated the non-inferiority of mitiglinide 10 - 20 mg versus nateglinide 120 mg, given orally three times daily for 20 weeks, in 291 Chinese type 2 diabetes mellitus (DM) patients in whom adequate blood glucose control had not
Lisa Kitasato et al.
Cardiovascular diabetology, 11, 79-79 (2012-07-04)
The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and
Kohei Kaku et al.
Endocrine journal, 56(6), 739-746 (2009-06-10)
This study was performed to examine the efficacy and safety of the rapid- and short-acting insulinotropic SUR ligand mitiglinide given as add-on therapy for 52 weeks in type 2 diabetic patients whose blood glucose was insufficiently controlled by pioglitazone monotherapy.
Bo Wang et al.
Cytokine, 57(2), 300-303 (2011-12-02)
Fibroblast growth factor 21 (FGF-21) has been identified as a potent metabolic regulator. Despite the importance of FGF-21 in the regulation of glucose, lipid and energy homeostasis, much less is known about the effect of common anti-diabetic treatment on the
Masanori Abe et al.
Expert opinion on pharmacotherapy, 11(2), 169-176 (2009-12-23)
Mitiglinide, a rapid- and short-acting insulinotropic sulfonylurea receptor ligand, exhibits hypoglycemic action unlike other sulfonylureas. The efficacy of the combination of mitiglinide and alpha-glucosidase inhibitors for diabetic patients on hemodialysis (HD) has not been prospectively evaluated; therefore, we evaluated the

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service